Genomic characterization reveals potential biomarkers in nasopharyngeal carcinoma patients with relapse

References

• Chua ML, Wee JT, Hui EP, et al. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012–1024.
   PubMed Web of Science ®Google Scholar
• Bruce JP, Yip K, Bratman SV, et al. Nasopharyngeal cancer: molecular landscape. J Clin Oncol. 2015;33(29):3346–3355.
   PubMed Web of Science ®Google Scholar
• Almobarak AA, Jebreel AB, Abu-Zaid A. Molecular targeted therapy in the management of recurrent and metastatic nasopharyngeal carcinoma: A comprehensive literature review. Cureus. 2019;11(3):e4210.
   PubMed Web of Science ®Google Scholar
• Masterson L, Howard J, Gonzalez-Cruz J, et al. Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: beyond an era of chemoradiation? Int J Cancer. 2020;146(8):2305–2314.
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Gao J, Phillips SM, et al. OncoKB: A precision oncology knowledge base. JCO Precis Oncol. 2017;2017. DOI:10.1200/PO.17.00011.
   Google Scholar
• Cho WC, Tan KT, Ma VW, et al. Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer. Oncotarget. 2018;9(91):36344–36357.
   PubMedGoogle Scholar
• Chang SC, Lai YC, Chang CY, et al. Concomitant genetic alterations are associated with worse clinical outcome in EGFR mutant NSCLC patients treated with tyrosine kinase inhibitors. Transl Oncol. 2019;12(11):1425–1431.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Zhang Z, et al. Prognostic value of the Epstein-Barr virus and tumor suppressor gene p53 gene in nasopharyngeal squamous cell carcinoma. J Cancer Res Ther. 2019;15(2):426–436.
   PubMed Web of Science ®Google Scholar
• Ginzinger DG, Godfrey TE, Nigro J, et al. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res. 2000;60(19):5405–5409.
   PubMed Web of Science ®Google Scholar
• Buffart TE, van Grieken NC, Tijssen M, et al. High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch. 2009;455(3):213–223.
   PubMed Web of Science ®Google Scholar
• Lautenschlaeger T, George A, Klimowicz AC, et al. Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival. Oncologist. 2013;18(6):685–686.
   PubMed Web of Science ®Google Scholar
• Schwaederlé M, Lazar V, Validire P, et al. VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer: implications for antiangiogenesis therapy. Cancer Res. 2015;75(7):1187–1190.
   PubMed Web of Science ®Google Scholar
• Koehler K, Liebner D, Chen JL. TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol. 2016;27(3):539–543.
   PubMed Web of Science ®Google Scholar
• Xia Y, Xu-Monette ZY, Tzankov A, et al. Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 2016;31(3):625–636.
   PubMed Web of Science ®Google Scholar
• Domingo E, Camps C, Kaisaki PJ, et al. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. Lancet Gastroenterol Hepatol. 2018;3(9):635–643.
   PubMed Web of Science ®Google Scholar
• Filipits M, Dafni U, Gnant M, et al. Association of p27 and cyclin D1 expression and benefit from adjuvant trastuzumab treatment in HER2–positive early breast cancer: A transHERA study. Clin Cancer Res. 2018;24(13):3079–3086.
   PubMed Web of Science ®Google Scholar
• Olanich ME, Sun W, Hewitt SM, et al. CDK4 amplification reduces sensitivity to CDK4/6 inhibition in fusion-positive rhabdomyosarcoma. Clin Cancer Res. 2015;21(21):4947–4959.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Schwartz GK, Keohan ML, et al. Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib. JAMA Oncol. 2016;2(7):937–940.
   PubMed Web of Science ®Google Scholar
• Yang L, Chen S, Luo P, et al. Liposarcoma: advances in cellular and molecular genetics alterations and corresponding clinical treatment. J Cancer. 2020;11(1):100–107.
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116–129.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–348.
   PubMed Web of Science ®Google Scholar
• Barreca A, Lasorsa E, Riera L, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol. 2011;47(1):R11–R23.
   PubMed Web of Science ®Google Scholar
• Tabbó F, Barreca A, Piva R, et al. ALK signaling and target therapy in anaplastic large cell lymphoma. Front Oncol. 2012;2:41.
   PubMedGoogle Scholar
• Murga-Zamalloa C, Lim MS. ALK-driven tumors and targeted therapy: focus on crizotinib. Pharmacogenomics Person Med. 2014;7:87–94.
   PubMedGoogle Scholar
• Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12(1):68–78.
   PubMed Web of Science ®Google Scholar
• Faraoni I, Graziani G. Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. Cancer. 2018;10(12):487.
   Google Scholar
• Knappskog S, Leirvaag B, Gansmo LB, et al. Prevalence of the CHEK2 R95* germline mutation. Hered Cancer Clin Pract. 2016;14:19.
   PubMed Web of Science ®Google Scholar
• Abud J, Koehler-Santos P, Ashton-Prolla P, et al. CHEK2 1100DELC germline mutation: a frequency study in hereditary breast and colon cancer Brazilian families. Arq Gastroenterol. 2012;49(4):273–278.
   PubMedGoogle Scholar